Molecular diagnostic assay modeling and quality control optimization for robust personalised cancer risk assessment

BioLizard supported Mdxhealth in developing a robust prostate cancer risk scoring model and optimizing triplex assay QC. By refining analytics, SOPs, and QC workflows, we enhanced predictive accuracy, reproducibility, and operational efficiency for personalized diagnostics.

Mdxhealth is a front runner in epigenetic research with a proven track record of identifying, developing, validating and delivering molecular diagnostic assays. They provide functional genomic data that can be used for personalised cancer risk assessment, with specific focus on prostate cancer.

Teamwork

Project 1 overview: Molecular diagnostic assay modeling

BioLizard assisted with development and optimisation of a robust model to calculate patient risk score for prostate cancer based on clinical biomarkers and other clinical features.

Wet lab

Project 2 overview: Molecular diagnostic triplex assay QC optimisation

The goal was to optimize the client’s current qualification of reagents and equipment. Instead of a head-to-head approach, we developed a QC panel that can be used in each run to see if they fall in between the expected QC ranges.

“We were very pleased with the work BioLizard did. The BioLizard team were very flexible and took the necessary time to fully understand our needs. Their tailored service allowed us to draw meaningful conclusions from our data.” – Mdxhealth

Our approach

Molecular diagnostic assay model

  • Model building to optimize clinical assay and patient risk score predictions based on a clinical biomarker panel
  • Leverage advanced analytics to develop robust and personalized patient risk scoring algorithms
  • Write SOPs
  • Calculate performance on clinical cohorts

Molecular diagnostic triplex assay QC optimisation

  • Based on historical data, develop expected range to be used as QC range
  • Develop criteria for releasing new items (new reagent batch and/or equipment)
  • For day-to-day QC: Analyze calibrator values, generate expected range + compare different setups

Results

SOPs
  • Provided detailed SOPs
  • Created a robust patient risk scoring model
  • Identified a potential breakthrough biomarker
  • Provided detailed model documentation for NY State Dept. of Health Review
QC
  • Day–to-day QC with robust ranges for better reproducibility and quality with less time, waste, and reagents
  • Improved research efficiency & capture of largest market share

For more information contact us today!

https://139582766.hs-sites-eu1.com/hs-web-interactive-139582766-76449037512

Work was performed in collaboration with Mdxhealth.

mdxhealth-logo-full-color-rgb
How spatial biology improves clinical trial success in oncology

How spatial biology improves clinical trial success in oncology

In oncology, the drug development path is unique: Phase 0 and Phase I trials are typically conducted in patients rather than healthy volunteers, allowing for early assessment of efficacy and patient selection alongside safety. Yet, even with this early clinical insight, many cancer drugs show promise in the lab but fail to transition effectively into the clinic. This often happens because, while we verify that a drug’s target is present, we frequently overlook its context, specifically its location, the surrounding microenvironment, and its interaction with neighboring cells. By revisiting real-world examples of discontinued trials, this post explains why understanding the “where” is just as critical as the “what”, and how spatial biology is positioning itself as a valuable avenue for validating clinical potential.

Why bioinformatics workflows require experienced software engineers

Bioinformatics pipelines break for the smallest reasons: package updates, shifting dependencies, or “it only works on my machine.” This post explains why experienced software engineers and DevOps practices (Git, CI/CD, IaC) are essential to keep workflows reproducible, stable, and scalable.